175 related articles for article (PubMed ID: 37016431)
1. NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization.
Narang S; Evensen NA; Saliba J; Pierro J; Loh ML; Brown PA; Kolekar P; Mulder H; Shao Y; Easton J; Ma X; Tsirigos A; Carroll WL
Genome Biol; 2023 Apr; 24(1):64. PubMed ID: 37016431
[TBL] [Abstract][Full Text] [Related]
2. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
[TBL] [Abstract][Full Text] [Related]
3. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
[TBL] [Abstract][Full Text] [Related]
4. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
Jaffe JD; Wang Y; Chan HM; Zhang J; Huether R; Kryukov GV; Bhang HE; Taylor JE; Hu M; Englund NP; Yan F; Wang Z; Robert McDonald E; Wei L; Ma J; Easton J; Yu Z; deBeaumount R; Gibaja V; Venkatesan K; Schlegel R; Sellers WR; Keen N; Liu J; Caponigro G; Barretina J; Cooke VG; Mullighan C; Carr SA; Downing JR; Garraway LA; Stegmeier F
Nat Genet; 2013 Nov; 45(11):1386-91. PubMed ID: 24076604
[TBL] [Abstract][Full Text] [Related]
5. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
[TBL] [Abstract][Full Text] [Related]
6. NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains.
Lhoumaud P; Badri S; Rodriguez-Hernaez J; Sakellaropoulos T; Sethia G; Kloetgen A; Cornwell M; Bhattacharyya S; Ay F; Bonneau R; Tsirigos A; Skok JA
Nat Commun; 2019 Oct; 10(1):4843. PubMed ID: 31649247
[TBL] [Abstract][Full Text] [Related]
7. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
8. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
9. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
10. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract][Full Text] [Related]
11. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance.
Saint Fleur-Lominy S; Evensen NA; Bhatla T; Sethia G; Narang S; Choi JH; Ma X; Yang JJ; Kelly S; Raetz E; Harvey RC; Willman C; Loh ML; Hunger SP; Brown PA; Getz KM; Meydan C; Mason CE; Tsirigos A; Carroll WL
Cancer Res; 2020 Dec; 80(23):5189-5202. PubMed ID: 33067268
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
Hanley RP; Nie DY; Tabor JR; Li F; Sobh A; Xu C; Barker NK; Dilworth D; Hajian T; Gibson E; Szewczyk MM; Brown PJ; Barsyte-Lovejoy D; Herring LE; Wang GG; Licht JD; Vedadi M; Arrowsmith CH; James LI
J Am Chem Soc; 2023 Apr; 145(14):8176-8188. PubMed ID: 36976643
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia.
Yang M; Vesterlund M; Siavelis I; Moura-Castro LH; Castor A; Fioretos T; Jafari R; Lilljebjörn H; Odom DT; Olsson L; Ravi N; Woodward EL; Harewood L; Lehtiö J; Paulsson K
Nat Commun; 2019 Apr; 10(1):1519. PubMed ID: 30944321
[TBL] [Abstract][Full Text] [Related]
15. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
[TBL] [Abstract][Full Text] [Related]
16. Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia.
Wang H; Sun H; Liang B; Zhang F; Yang F; Cui B; Ding L; Wang X; Wang R; Cai J; Tang Y; Rao J; Hu W; Zhao S; Wu W; Chen X; Wu K; Lai J; Xie Y; Li B; Tang J; Shen S; Liu Y
Nat Commun; 2023 Oct; 14(1):6792. PubMed ID: 37880218
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia.
Kloetgen A; Thandapani P; Ntziachristos P; Ghebrechristos Y; Nomikou S; Lazaris C; Chen X; Hu H; Bakogianni S; Wang J; Fu Y; Boccalatte F; Zhong H; Paietta E; Trimarchi T; Zhu Y; Van Vlierberghe P; Inghirami GG; Lionnet T; Aifantis I; Tsirigos A
Nat Genet; 2020 Apr; 52(4):388-400. PubMed ID: 32203470
[TBL] [Abstract][Full Text] [Related]
18.
Contreras Yametti GP; Robbins G; Chowdhury A; Narang S; Ostrow TH; Kilberg H; Greenberg J; Kramer L; Raetz E; Tsirigos A; Evensen NA; Carroll WL
Leuk Lymphoma; 2024 Jan; 65(1):78-90. PubMed ID: 37874744
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
